Archive | Next Phase Archive RSS feed for this section

RESI Partnering Tips: How to Fill Your Day with Meetings on January 14th

12 Dec

By Bryanna Allison, Business Development Manager, LSN

If you’ve registered for RESI San Francisco, then it’s likely that your goal is to book a strong slate of meetings, followed by a full day of face-to-face meetings with investors at RESI.  Here is our advice for partnering success at RESI:

  • Fill out your profile! This will provide investors with information above and beyond what you can fit in your intro message. If you fill out the key fields in your profile, attendees can revert back there for more information.
  • Use the filters in the sidebar when searching for meeting partners! Whether you are a startup, investor or service provider, the filters are in place to make your lives easier. You can pick a category of attendees to search, then use the filters to narrow down to the most relevant fits for you, such as investors who are interested in your sector.
  • Send as many relevant meeting requests as possible. Always use the “book a meeting” option for initial contact.
  • Put effort into the message you are sending along with your meeting requests. Tell them what you’re doing, who you are, why you’d be a great fit to work together and what you’re looking to get out of the relationship. Keep it concise, but informative!
  • Follow up on your requests. You can use the “send a message” option in RESI Partnering to send follow-up notes, or if you have the investor’s contact info you could send an email directly.
  • Continue to check the platform regularly. New investors, startup and service provider attendees are added every day. If you want to focus on newly added profiles, you can change the order of search results from ‘Order alphabetically’ to ‘Order by date approved’ and look at who’s joined since your last visit.
  • Join our partnering tutorials so you can see it all firsthand! Please visit our website for the complete partnering tutorial schedule.
  • Bring your partnering schedule to RESI – either print it out or have it available on your phone.

Using the partnering platform effectively can help you make the most out of RESI! It’s there so you know exactly who is coming and exactly who you need to talk to. Don’t miss out on our largest event of the year and this excellent opportunity to network with over 500 life science investors.

Attend the Enmore Bio Conference to Connect with China’s Bio Industry – Suzhou, China February 20-22, 2020

12 Dec

By Candice He, Global Investment Strategist, LSN

As a co-organizer of RESI Shanghai, Enmore has become a valuable partner of Life Science Nation, utilizing their expertise in the local market and as conference organizers to make RESI a success, with more than 450 investors, startups and service providers in attendance. LSN and Enmore have a common goal of creating an international ecosystem for advancing life science technologies to market in a global economy, and will continue to partner to achieve this. For those interested in exploring the China market and establishing relationships with key players in the China life science ecosystem, we invite you to attend the Enmore Bio Conference, taking place at the Suzhou International Expo Center from February 20-22, 2020.

What is EBC?

Enmore Bio Conference (EBC) is the largest and most influential bio-industry conference in China, as well as the most open conference platform jointly created by Enmore Healthcare, the organizer, and many industry associations, institutions, companies and experts for the whole industry chain.

EBC consists of four parallel conferences: the 10th Antibody Drugs & Novel Biological Summit, the 8th Molecular Diagnostics Summit, the 6th Immunotherapy Industry Summit, and the 3rd 17TALK Healthcare Investment & Financing Leadership Forum. The four-in-one event covers topics concerning the whole industry chain of diagnosis, treatment and medication, and other topics like CDx, target development, clinical research and policy discussion will also be touched through a dozen of special forums. The Enmore Bio Exhibition, as part of this event, will attract more than 200 suppliers of instruments, consumables and services. The EBC, which combines conference and exhibition, has become a benchmark platform for high-level exchanges and cooperation in the bio-industry in China and abroad.

Conference website:

Why choose EBC?

EBC is committed to building China’s largest and most influential bio industry event through four parallel conferences, a dozen of co-organized forums, three invited-only meetings for CEOs and pre-event business visits. More than 150 enterprise leaders and experts will make presentations during this event.

Previous reports of EBC:

Co-organizations of EBC 2020

Guangzhou KingMed Diagnostics Group Co., Ltd.


Wuhan Tongji Hospital

Renmin Hospital Of Wuhan University

Shanghai Junshi Biosciences Co., Ltd.

Hengrui Medcine

Innoforce Pharmaceuticals Co., Ltd.

TOT Biopharm


Everbright Medical & Healthcare Fund

EBC parallel conferences:

10th Antibody Drugs & Novel Biological Summit

The 10th Antibody Drugs & Novel Biological Summit is co-organized by Junshi Biosciences, Hengrui Medicine, Innoforce Pharmaceuticals, TOT BIOPHARM and SAPA-China. It covers the whole process of early research and development, process development, mass production, industrialization and commercialization. We will bring together CEOs and top leaders of functional departments of local listed companies, as well as heads of R&D, production, quality, process and business of antibody enterprises at home and abroad through a platform of exchanges and cooperation for thousands of people.

8th Molecular Diagnostics Summit

The 8th Molecular Diagnostics Summit is co-organized by Enmore and KingMed Diagnostics. This time we focus on “molecular diagnostics market structure and corporate strategy”, “multi-platform detection technology for clinical diagnosis” and “to create competitive molecular diagnostic products”. Authoritative experts in precision medicine and outstanding enterprises such as Jiangsu Center for Clinical Laboratories, Shanghai Center for Clinical Laboratory, Berry Genomics, Geneseeq, and KingMed Diagnostics Group will participate in this summit. An invited-only CEO meeting will happen during the summit, organized by Clinical Laboratories leaders.

6th Immunotherapy Industry Summit

The 6th Immunotherapy Industry Summit aims to provide businesses with the industrialization of cellular immunotherapy in the next two years. The forum is jointly developed by experts and scholars in the field of cellular immunotherapy study, quality control leaders of first-tier companies, and CEOs of domestic and foreign companies with extensive industrialization experience! Companies and institutions involved include Fosun Kite Biotechnology Co., Ltd, JW Therapeutics, Cellular Biomedicine Group, PersonGene, Tongji Hospital, etc.

3rd 17TALK Healthcare Investment & Financing Leadership Forum

The 3rd 17TALK Healthcare Investment & Financing Leadership Forum is co-hosted by Enmore Healthcare and Everbright Medical & Healthcare Fund. The forum features healthcare investment trends and corporate listing, inviting local and international top investors to participate in the discussions. Special financing roadshows will be held to provide a financing platform for enterprises.

Who will attend EBC?

EBC 2019 attracted 2,208 attendees, and EBC 2020 is expected to exceed 3,000 attendees. The participating groups include entrepreneurs, scientists, clinicians, investors and suppliers, mostly CEOs and heads of R&D, production, quality, process and commercialization.

Part of EBC 2019 attendees

Antibody Drugs BIO-THERA Immunotherapy Gracell
Antibody Drugs BeiGene Immunotherapy Lion TCR
Antibody Drugs JOINN Laboratories (Beijing) Immunotherapy HRYZ BIO TECH CO.
Antibody Drugs Boehringer-Ingelheim Immunotherapy GENE
Antibody Drugs KANGHONG PHARMACEUTICAL Immunotherapy CARsgen Therapeutics
Antibody Drugs TOT BIOPHARM Immunotherapy Nanjing Legend Pharmaceutical & Chemical Co., Ltd
Antibody Drugs HARBOUR Immunotherapy Genscript
Antibody Drugs Hutchison MediPharma Immunotherapy IASO BIO
Antibody Drugs NCPC Immunotherapy Innovative Cellular Therapeutics Co.,Ltd.
Antibody Drugs CR PHARMA COMM Immunotherapy Shanghai Cell Therapy Group Co.LTD
Antibody Drugs Pfizer Immunotherapy JW Therapeutics
Antibody Drugs Genor Biopharma Co. Ltd. Immunotherapy Cellular Biomedicine Group
Antibody Drugs Alphamab Co. Ltd Immunotherapy Eureka Therapeutics, Inc
Antibody Drugs Elpiscience Immunotherapy Vcanbio
Antibody Drugs Livzon International Limited Molecular Diagnostics Eppendorf
Antibody Drugs Lunan Pharmaceutical Group Molecular Diagnostics ACON Laboratories
Antibody Drugs Transcenta Molecular Diagnostics Genetron Health
Antibody Drugs Mabtech Limited Molecular Diagnostics Leadmanbio
Antibody Drugs GenScript Biotech Corporation Molecular Diagnostics DIAN DIAGNOSTICS GROUP CO LTD
Antibody Drugs Qilu Pharmaceutical Molecular Diagnostics Berryoncology
Antibody Drugs Johnson&Johnson Molecular Diagnostics Guangzhou KingMed Diagnostics Group Co., Ltd.
Antibody Drugs Humanwell Healthcare Molecular Diagnostics Sansure Biotech Inc.
Antibody Drugs RemeGen Molecular Diagnostics BGI
Antibody Drugs ChemPartner Molecular Diagnostics Getein Biotech, Inc.
Antibody Drugs 3SBIO INC. Molecular Diagnostics Singlera Genomics
Antibody Drugs Luye Pharma Group Molecular Diagnostics Luminex Corporation
Antibody Drugs EpimAb Biotherapeutics Molecular Diagnostics Roche diagnostics (shanghai) limited
Antibody Drugs Henlius Molecular Diagnostics Geneseeq Technology Inc.
Antibody Drugs JMT-BIO Molecular Diagnostics PerkinElmer
Antibody Drugs Shanghai Junshi Biosciences Co., Ltd. Molecular Diagnostics Hitachi
Antibody Drugs Etana Biotechnologies Hong Kong Limited Molecular Diagnostics Amoy Diagnostics
Antibody Drugs Roche Molecular Diagnostics Shanghai Kehua Bio-Engineering Co., Ltd.
Antibody Drugs Shanghai Miracogen Inc. Molecular Diagnostics 3dmedcare
Antibody Drugs NewBio Therapeutics, Inc. Molecular Diagnostics Liferiver Bio–Tech
Antibody Drugs Wuxi AppTec Molecular Diagnostics HaploX
Antibody Drugs Klus Pharma Inc. Molecular Diagnostics Shenzhen New Industries Biomedical Engineering Co., Ltd.
Antibody Drugs Suzhou Yabao Pharmaceutical R&D Co., Ltd. Molecular Diagnostics Wuhan YZY Medical Science&Technology Co.,Ltd
Antibody Drugs Tasly Group Molecular Diagnostics simceredx
Antibody Drugs Simcere Pharmaceutical Group Molecular Diagnostics Abbottmama
Antibody Drugs Innovent Molecular Diagnostics Autobio
Antibody Drugs YST Molecular Diagnostics Vcanbio
Antibody Drugs WuXi Biologics Investment Northern Light Venture Capital
Antibody Drugs Yichang Humanwell Pharmaceutical Co., Ltd Investment DeCheng Capital
Antibody Drugs Zai Lab Investment GTJA INVESTMENT GROUP
Antibody Drugs HISUN Investment GUOTAI JUNAN Securities
Antibody Drugs Zhejiang Huahai Pharmaceutical Co., Ltd. Investment China SDIC GaoXin Industrial Investment Corp., Ltd
Antibody Drugs Teruisi Investment China Resources (Holdings) Co., Ltd.
Antibody Drugs CTTQ Investment Jemincare
Antibody Drugs Akeso Biopharma Investment Legend Capital
Immunotherapy IQVIA Investment Warburg Pincus
Immunotherapy PersonGene Investment PING AN Ventures
Immunotherapy BoyaLife Investment PWC
Immunotherapy Fosun Kite Biotechnology Co., Ltd Investment SBCVC
Immunotherapy Fosun Pharma Investment Oriza Holdings

Conference Agenda of EBC 2020

Registration at EBC

Online registration:


3 Days Until RESI SF Partnering Launches!

5 Dec

By Bryanna Allison, Business Development Manager, LSN

Mark your calendar for Monday, December 9th. The partnering portal for RESI San Francisco will launch around 11am EST! First things first, are you registered for the conference? You will only have access to the partnering portal after you have registered. If you haven’t, please don’t wait!  It’s an advantage to be in partnering at launch in order to get the first touch out to investors.

The RESI Conference was designed as a partnering conference to ensure every one of your meetings is worthwhile, based on a strong fit between company and investor.  RESI Partnering provides fully tagged profiles of all the investors attending, based on interview conducted by LSN’s Investor Research team.  Our RESI Premier Partnering attendees can also see in depth profiles on investor technology interests and get direct contact with investors.  Would you like to meet with these investors, and more?  Sign up for RESI now.


As of Dec. 3rd, 2019



Last Call for RESI SF Innovation Challenge Applications!

5 Dec

By Karen Deyo, Senior Investor Research Analyst, LSN

The deadline for applying to the RESI SF Innovation Challenge is tomorrow, Friday, Dec. 6th, and this is the last call for companies to submit their applications for consideration. The Innovation Challenge is a unique competition, where companies are selected using criteria such as innovativeness, stage of development, market size and opportunity and competitive landscape. The top companies, identified for their ‘investability,’ present posters in the exhibit hall on the day of the conference, competing for ‘investments’ of ‘RESI Cash’ from attendees to win prizes.

Participation in the Innovation Challenge can benefit finalists in many ways, including the increased exposure gained by the feature in the LSN Newsletter, the printed RESI Program Guide, as well as onsite signage at RESI. In addition, companies that actively seek ‘investments’ from attendees find that this can lead to many productive ad hoc meetings, furthering their fundraising campaigns in sometimes unexpected ways.

Click here to apply to the Innovation Challenge – good luck!


Artificial Intelligence is the Future of Healthcare

5 Dec

By Lucy Parkinson, VP of Investor Research, LSN

At LSN we speak to investors day in, day out, about what technologies they are seeking for their future portfolios. Many are now looking for artificial intelligence (AI) solutions across all of the sectors that LSN covers – drugs, devices, diagnostics and digital health. Investors are interested in the power of AI: from drug discovery tools to data analytics, from genomics to clinical decision support, and also including image analysis and patient monitoring, to name a few.

It’s clear that there is an emerging interest in bringing these fields together. LSN has already used RESI to dip our toes in the water of AI, with regular panels on AI in Healthcare; at RESI Taipei, Professor Jack Li delivered a presentation on the future AI landscape of healthcare, which highlighted the role AI can play in lowering the costs of future care delivery. We’ve found these topics have resonated with both investors and entrepreneurs in early stage life sciences. There are many avenues for adding AI as an extra dimension to new technologies, such as using AI to analyze data from new drugs or devices.

RESI San Francisco will include two investor panels specifically devoted to artificial intelligence: the broad AI in Healthcare panel, and a more focused panel on AI in Pathology and Imaging, a key sector for the advancement of healthcare AI.  AI is also a key topic in other panels such as Oncology Innovation and Investing in Life Science Tools.  With so much innovation happening in this space, RESI hopes to help investors and entrepreneurs who are focused on healthcare AI connect with each other.

LSN is planning further dedicated content in this space; look out for the launch of 4D Meets AI soon.

Global Family Office BioForum to Sponsor RESI’s 2020 Events Worldwide

5 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

We are delighted to announce that the Global Family Office Bioforum (GFOB) will be RESI’s title sponsor for 2020.

The Global Family Office BioForum (GFOB) is the leading alliance of international Family Offices focused on healthcare/life science which meets quarterly in 18 cities in the US, Europe and Asia.  GFOB also has a joint partnership with Life Science Nation and the RESI conference Series. These initiatives aim to assist the earliest stage life sciences companies by sourcing seed capital and management talent.


Life Science Nation’s, Focus on Cures Accelerator (FOC), Now Offering a Fundraising Campaign Curriculum

27 Nov

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN recently launched the Focus on Cures (FOC) Accelerator that helps high-growth, international startup companies move into the global partnering arena through a two-week Boston-based immersion program, titled MKT 466: Funding and Partnering Immersion Course, integrated into LSN’s global partnering network and the RESI conference series. The theme of the FOC accelerator is to create a funnel of elite, top domestic and foreign startups that need to raise angel, seed, series A and B rounds. This course solves an early stage funding challenge: there is no standardized methodology for teaching a company how to brand and message itself and efficiently manage a fundraising campaign. There is no reliable, accurate, and current partner and investor database (besides LSN’s) to get a company a list of global partners that are a fit for their stage of development and product set. Very few entrepreneurs are actually taught how to launch and manage a fundraising campaign, never mind training CEOs how to make an introductory phone call or write an introductory email. Most importantly, no one teaches the holy grail of canvassing for capital, which is, how to follow up.

– Incubator
– Accelerator
– Government Agency
– Private Firm Seeking Funding

Participants in the course receive:

  • A year subscription to the LSN investor database, valued at $6,995
  • Branding and messaging collateral for fund raising campaign, (including a logo, tagline, one page data sheet, two page executive summary, and 10-12 slide pitch), valued at $15K
  • A ticket to the next RESI conference to launch the fundraising campaign, valued at $3,000

The course is $10,000 per company, for services valued at $25,000, held at the LSN corporate headquarters in Downtown Crossing, Boston. Each company is expected to send one business and one science executive for the two week immersion class. The first class will be held from May 25th through Jun 5th, leading up to RESI San Diego, taking place on Monday, June 8th.

FOC Accelerator – MKT 466 Funding and Partnering Immersion Course

MKT466 is a unique two-week immersion course designed for life science entrepreneurs to experience the best methodologies for reaching out and establishing a dialogue with partners and  investors, building a relationship and, ultimately, securing capital allocations.

The morning sessions are 3-hour classes teaching the fundamental business development and marketing skills needed to formulate a company theme, create a corporate brand with appropriate messaging and market your firm to investors and strategic partners within the life science arena. (See details in the morning class outline)

The afternoon sessions include 1 hour of meeting the players in the Massachusetts life science ecosystem and 2 hours of curating and reaching out to a list of global investors and channel partners:

  1. Utilize LSN’s Company Database to build a full picture of global landscape of competitors
  2. Utilize LSN’s Investor Database to find investors and partners that are a fit for your stage of development and product set and aggregate a global target list
  3. Refine investor-centric marketing collateral (following the instructions of the Branding and Messaging class)
  4. Leverage your infrastructure to do email marketing campaigns and nurture leads in a CRM
  5. Start email and phone canvassing each day, supervised and mentored by LSN expert BD staff
  6. Set up intro phone calls and meetings
  7. Prepare for the upcoming RESI conference
%d bloggers like this: